Skip to content

Ina Vukalović

4 papers in the library · 6 citations · publishing 2026

Papers

Sort Most recent Most cited

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology July 1, 2026 Denis Arikci, Joran Borgulya, Isabelle Straumann et al. 1 citation

Based on its in vitro profile and preliminary evidence, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) may have psychoactive properties that are similar to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which are investigated for the treatment of posttraumatic stress disorder and depressive disorders. We compared acute effects of 2C-B (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin...

DOI: 10.1038/s41386-026-02428-9 (opens in new tab) Full text (opens in new tab)

Comparison of acute effects of 3,4-methylenedioxymethamphetamine (MDMA) with and without a supplemental booster dose in healthy participants: a double-blind, randomized, placebo-controlled, crossover study

Translational Psychiatry June 4, 2026 Mélusine Humbert‐droz, Anna M Becker, Jan Valenta et al.

3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is being investigated as a treatment for several psychiatric disorders, particularly posttraumatic stress disorder. Phase 2 and 3 trials typically administered a first dose of MDMA followed by a second "booster" dose 1.5-2.5 h later, to extend the acute effect duration. However, the risks and benefits of the booster dose...

DOI: 10.1038/s41398-026-04148-6 (opens in new tab) Full text (opens in new tab) MDMA Ecstasy Placebo Adverse effect +6

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants

Translational Psychiatry March 27, 2026 Livio Erne, Lorenz Mueller, Isabelle Straumann et al.

N,N-dimethyltryptamine (DMT) is a serotonergic psychedelic that produces short-lived peak effects when administered intravenously as a bolus dose. Initial trials suggested therapeutic effects of DMT in depressive disorders. However, systematic data on dose-dependent pharmacokinetics and acute effects of intravenous bolus DMT administration are currently lacking. We used a double-blind,...

DOI: 10.1038/s41398-026-03987-7 (opens in new tab) Full text (opens in new tab) Tolerability Pharmacokinetics Crossover study Placebo +7

Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2026 Isabelle Straumann, Patrick Vizeli, Isidora Avedisian et al. 5 citations

3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally, as a research tool, and in MDMA-assisted therapy in patients with posttraumatic stress disorder. 3,4-Methylenedioxyamphetamine (MDA) is a psychoactive metabolite of MDMA. Acute effects of MDMA and MDA have never been directly compared in humans. Lysine-conjugated amphetamines slowly release active amphetamine once absorbed,...

DOI: 10.1038/s41386-025-02248-3 (opens in new tab) Full text (opens in new tab)